This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hong, Y. Articles by McLachlan, A. J. Search for Related Content PubMed PubMed Citation Articles by Hong, Y. Articles by McLachlan, A. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2006, p. 935-942, Vol. 50, No. 3
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.3.935-942.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Population Pharmacokinetics of Liposomal Amphotericin B in Pediatric Patients with Malignant Diseases

Ying Hong,^1, Peter J. Shaw,² Christa E. Nath,³ Satya P. Yadav,² Katherine R. Stephen,² John W. Earl,³ and Andrew J. McLachlan^1*

Faculty of Pharmacy, University of Sydney,¹ Department of Oncology,² Department of Biochemistry, the Children's Hospital at Westmead, Sydney, NSW, Australia³

Received 21 June 2005/ Returned for modification 30 September 2005/ Accepted 27 December 2005

A population pharmacokinetic model of liposomal amphotericin B (L-AmB) in pediatric patients with malignant diseases was developed and evaluated. Blood samples were collected from 39 pediatric oncology patients who received multiple doses of L-AmB with a dose range from 0.8 to 5.9 mg/kg of body weight/day. The patient cohort had an average age of 7 years (range, 0.2 to 17 years) and weighed an average of 28.8 ± 19.8 kg. Population pharmacokinetic analyses were performed with NONMEM software. Pharmacokinetic parameters, interindividual variability (IIV), between-occasion variability (BOV), and intraindividual variability were estimated. The influence of patient characteristics on the pharmacokinetics of L-AmB was explored. The final population pharmacokinetic model was evaluated by using a bootstrap sampling technique. The L-AmB plasma concentration-time data was described by a two-compartment pharmacokinetic model with zero-order input and first-order elimination. The population mean estimates of clearance (CL) and volume of distribution in the central compartment (V₁) were 0.44 liters/h and 3.12 liters, respectively, and exhibited IIV (CL, 10%) and significant BOV (CL, 46% and V₁, 56%). The covariate models were CL (liters/h) = 0.44 · e^{0.0152 ·(WT – 21)} and V₁ (liters) = 3.12 · e^{0.0241 · (WT – 21)}, where WT is the patient's body weight (kg) centered on the study population cohort median of 21 kg. Model evaluation by the bootstrap procedure indicated that the full pharmacokinetic model was robust and parameter estimates were accurate. In conclusion, the pharmacokinetics of L-AmB in pediatric oncology patients were adequately described by the developed population model. The model has been evaluated and can be used in the design of rational dosing strategies for L-AmB antifungal therapy in this special population.

Present address: Department of Pharmaceutical Sciences, University at Buffalo, SUNY.

This article has been cited by other articles:

• Goodwin, M. L., Drew, R. H. (2008). Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 61: 17-25 [Abstract] [Full Text]